Carolyn Rebeiro from Mining.com.au sits down with ABx Group Limited (ASX:ABX) Managing Director and CEO Dr Mark Cooksey and Corporate Connect Senior Equities Analyst Richard Close for an in-depth look at the company and its value proposition.
Copyright 2023 – Finance News Network
Source: Finance News Network
23 Oct 2019 - Cashwerkz Limited (ASX:CWZ) Executive Director, Craig Swanger talks about the company's platform, the benefit it provides for both banks and investors, FY19 results and outlook.
Read More08 Dec 2021 - Altech Chemicals Limited (ASX:ATC) Managing Director Iggy Tan discusses the cracking of the "silicon barrier" in order to significantly increase the energy retention and capacity of lithium-ion batteries for electric vehicles.
Read More06 Nov 2024 - Paul Sanger interviewed Damian Spring, CEO of Santana Minerals Limited (ASX:SMI), to discuss the Bendigo gold project, which has recently been designated as a fast-track project.
Read More03 Feb 2025 - Capital Prudential's Sam Moore on unlocking property development opportunities.
Read More27 Aug 2021 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes provides an update on sales and distribution for the company's Automated Plate Assessment System (APAS), which is used to read culture plates in laboratories.
Read More13 Dec 2023 - Chilwa Minerals Limited (ASX:CHW) Managing Director Cadell Buss discusses surprising drilling results and outlines future exploration plans.
Read More16 Oct 2023 - Damon Dorman, the Managing Director at Golden Mile Resources (ASX:G88), discusses the discovery of vermiculite in their Quicksilver Nickel project in Western Australia.
Read More17 May 2024 - Dotz Nano Limited (ASX:DTZ) Director Glenn Kelly discusses the carbon capture market and the different technologies available.
Read More12 Nov 2021 - Novatti Group Limited (ASX:NOV) CEO Peter Cook talks about the company's acquiring business and recent licences with Visa and Mastercard.
Read More19 Aug 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases.
Read More
